Search results for "apolipoprotein"

showing 10 items of 354 documents

Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency

2015

Backgrounds and aims: Adrenal insufficiency (AI) has been reported in patients with stable cirrhosis. A lack of substrates has been suggested as a possible contributing pathogenic mechanism leading to glucocorticoid deficiency in these subjects. To better explore this hypothesis, we studied lipoproteins in cirrhotics with and without AI. Methods. A total of 81 cirrhotic patients and 30 normal volunteers were enrolled. The severity of liver disease was graded by Child-Pugh score. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein AI (Apo-AI) levels were evaluated. HDL subfractions were measured by gradient gel electrop…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHydrocortisoneCohort StudiesLiver diseasechemistry.chemical_compoundHDL cholesterolInternal medicineHDL cholesterol; adrenal insufficiency; cirrhosismedicineAdrenal insufficiencyHumansTriglyceridesAgedHydrocortisoneApolipoprotein AICirrhosiApolipoprotein A-ITriglyceridebusiness.industrycirrhosisCholesterol HDLCase-control studyGastroenterologyMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologychemistryCase-Control StudiesMultivariate AnalysisFemalelipids (amino acids peptides and proteins)Lipoproteins HDLbusinessadrenal insufficiencyGlucocorticoidmedicine.drugLipoprotein
researchProduct

Garcinoic acid prevents β-amyloid (Aβ) deposition in the mouse brain

2020

Garcinoic acid (GA or δ-T3-13'COOH), is a natural vitamin E metabolite that has preliminarily been identified as a modulator of nuclear receptors involved in β-amyloid (Aβ) metabolism and progression of Alzheimer's disease (AD). In this study, we investigated GA's effects on Aβ oligomer formation and deposition. Specifically, we compared them with those of other vitamin E analogs and the soy isoflavone genistein, a natural agonist of peroxisome proliferator–activated receptor γ (PPARγ) that has therapeutic potential for managing AD. GA significantly reduced Aβ aggregation and accumulation in mouse cortical astrocytes. Similarly to genistein, GA up-regulated PPARγ expression and apolipoprote…

Male0301 basic medicineApolipoprotein EBiologiamedicine.medical_treatmentMetaboliteGenisteinFisiologiavitamin EPharmacologyProtein Aggregation PathologicalBiochemistry)protein aggregationgenisteinMiceProtein Aggregates03 medical and health scienceschemistry.chemical_compoundperoxisome proliferator-activated receptor gamma (PPARγ)neurodegenerative diseaseNeurobiologygarcinoic acidmedicineAnimalsBenzopyranstocotrienolReceptorMolecular BiologyPregnane X receptorAmyloid beta-Peptidespregnane X receptor (PXR)peroxisome proliferator-activated receptor (PPAR)030102 biochemistry & molecular biologyVitamin EBrainCell BiologyAlzheimer's diseasetocopherol030104 developmental biologyNuclear receptorchemistryperoxisome proliferator-activated receptor gamma (PPAR gamma)amyloid-beta (AB)apolipoprotein E (ApoETocotrienolAlzheimer diseaseapolipoprotein E (ApoE)
researchProduct

Associations of Genetic Susceptibility to Alzheimer’s Disease with Adiposity and Cardiometabolic Risk Factors among Children in a 2-Year Follow-up St…

2018

We investigated the associations of genetic risk score (GRS) for Alzheimer's disease and apolipoprotein E (APOE) ɛ variant with cardiometabolic risk factors during 2-year follow-up in children and whether body fat percentage (BF%) modify these associations. A population-based sample of 469 children (246 boys, 223 girls) at baseline and 398 children (201 boys, 197 girls) at 2-year follow-up participated in the study. Genotyping was performed using the Illumina Custom Infinium CardioMetabo BeadChip and the Illumina Infinium HumanCoreExome BeadChip. The GRS was calculated using information on nine independent gene variants available in our genomic data. We assessed BF%, waist circumference, in…

Male0301 basic medicineApolipoprotein Emedicine.medical_specialtyWaistPopulationBody fat percentage03 medical and health scienceschemistry.chemical_compoundApolipoproteins E0302 clinical medicineInsulin resistanceAlzheimer DiseaseRisk FactorsInternal medicineHumansMedicineGenetic Predisposition to DiseaseLongitudinal StudiesChildeducationAdiposityeducation.field_of_studybusiness.industryCholesterolGeneral NeuroscienceBody WeightGeneral Medicinemedicine.diseasePsychiatry and Mental healthClinical PsychologyCholesterol030104 developmental biologychemistryHomeostatic model assessmentFemaleInsulin ResistanceGeriatrics and GerontologyMetabolic syndromebusiness030217 neurology & neurosurgeryGenome-Wide Association StudyJournal of Alzheimer's Disease
researchProduct

Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-/- mice.

2018

Background The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation and ligand to both, pro-inflammatory cannabinoid receptor 1 (CB1) and anti-inflammatory CB2. While the role of both receptors in atherogenesis has been studied extensively, the significance of 2-AG for atherogenesis is less well characterized. Methods The impact of 2-AG on atherogenesis was studied in two treatment groups of ApoE-/- mice. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184 [5 mg/kg i.p.], which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received vehicle for four weeks. Simultaneously, both groups were fed a high-chole…

Male0301 basic medicineCCR1Chemokinelcsh:MedicineSmooth Muscle Cells030204 cardiovascular system & hematologyPathology and Laboratory MedicineBiochemistryMonocytesWhite Blood CellsMicechemistry.chemical_compoundChemokine receptorSpectrum Analysis Techniques0302 clinical medicinePiperidinesAnimal CellsCell MovementMedicine and Health SciencesReceptorlcsh:ScienceImmune ResponseJZL184MultidisciplinarybiologyNeurochemistryFlow CytometryLipidsCholesterolSpectrophotometryCytophotometryCellular TypesNeurochemicalsAnatomymedicine.symptomResearch Articlemedicine.medical_specialtyImmune CellsImmunologyMuscle TissueAntigens Differentiation MyelomonocyticInflammationArachidonic AcidsResearch and Analysis MethodsDiet High-FatCell LineGlycerides03 medical and health sciencesSigns and SymptomsApolipoproteins EDiagnostic MedicineAntigens CDInternal medicinemedicineAnimalsOil Red OBenzodioxolesInflammationMuscle CellsBlood CellsMacrophageslcsh:RBiology and Life SciencesCell BiologyAtherosclerosisMonoacylglycerol lipaseBiological Tissue030104 developmental biologyEndocrinologychemistrybiology.proteinlcsh:QEndocannabinoidsNeurosciencePLoS ONE
researchProduct

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hy…

2018

International audience; Background and Aim: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH.Methods and Results: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Netwo…

Male0301 basic medicineEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Low density lipoproteinDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compound0302 clinical medicineVascular inflammationeducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testGenetic disorderMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseLipidsUp-Regulation3. Good healthPhenotypeLow-density lipoproteinApolipoprotein B-100Femalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyStatin treatmentHypercholesterolemiaFamilial hypercholesterolemiaPopulationPhysical examinationHyperlipoproteinemia Type II03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansLipoprotein-associated phospholipase A2Plaque vulnerabilityeducationAgedApolipoprotein A-Ibusiness.industryCholesterol HDLCholesterol LDLStatin treatmentAtherosclerosisCardiovascular riskmedicine.diseaseCross-Sectional Studies030104 developmental biologychemistry1-Alkyl-2-acetylglycerophosphocholine EsteraseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersLipoproteinNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct

Apolipoprotein A2 Polymorphism Interacts with Intakes of Dairy Foods to Influence Body Weight in 2 U.S. Populations

2013

The interaction between a functional apolipoprotein A2 gene (APOA2) variant and saturated fatty acids (SFAs) for the outcome of body mass index (BMI) is among the most widely replicated gene-nutrient interactions. Whether this interaction can be extrapolated to food-based sources of SFAs, specifically dairy foods, is unexplored. Cross-sectional analyses were performed in 2 U.S. population–based samples. We evaluated interactions between dairy foods and APOA2 −265T > C (rs5082) for BMI in the Boston Puerto Rican Health Study (n = 955) and tested for replication in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study (n = 1116). Dairy products were evaluated as total dairy, hig…

MaleApolipoprotein A-IIPopulationMedicine (miscellaneous)BiologyBody Mass IndexFood groupmedicineHumansProspective StudiesFood scienceProspective cohort studyeducationAgededucation.field_of_studyNutrition and DieteticsBody WeightDietary managementBiochemical Molecular and Genetic MechanismsMiddle Agedmedicine.diseaseObesityUnited StatesApolipoprotein A2FemaleDairy ProductsBody mass indexApolipoprotein A-IIThe Journal of Nutrition
researchProduct

Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.

2002

Recent studies have shown that drugs that are normally unable to cross the blood-brain barrier (BBB) following intravenous injection can be transported across this barrier by binding to poly(butyl cyanoacrylate) nanoparticles and coating with polysorbate 80. However, the mechanism of this transport so far was not known. In the present paper, the possible involvement of apolipoproteins in the transport of nanoparticle-bound drugs into the brain is investigated. Poly(butyl cyanoacrylate) nanoparticles loaded with the hexapeptide dalargin were coated with the apolipoproteins AII, B, CII, E, or J without or after precoating with polysorbate 80. In addition, loperamide-loaded nanoparticles were …

MaleApolipoprotein BDrug delivery to the brainPharmaceutical SciencePolysorbatesMice TransgenicBlood–brain barrierchemistry.chemical_compoundMiceApolipoproteins EDrug Delivery SystemsmedicineAnimalsNanotechnologyPain MeasurementPolysorbateMice Inbred ICRbiologyChemistryBiological TransportMice Inbred C57BLmedicine.anatomical_structureApolipoproteinsTranscytosisBiochemistryBlood-Brain BarrierNanoparticles for drug delivery to the brainbiology.proteinBiophysicsDrug carrierLipoproteinJournal of drug targeting
researchProduct

Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial.

2011

Objectives: Apolipoprotein (Apo)B, ApoA-I, and their ratio could predict coronary heart disease (CHD) risk more accurately than conventional lipid measurements. Our aim was to assess the effect of a traditional Mediterranean diet (TMD) on apolipoproteins. Methods: High-cardiovascular risk subjects (n=551, 308 women and 243 men), aged 55-80 years, were recruited into a large, multicenter, randomized, controlled, parallel-group, clinical trial (The PREDIMED Study) aimed at testing the efficacy of TMD on primary cardiovascular disease prevention. Participants assigned to a low-fat diet (control) (n=177), or TMDs (TMD. +. virgin olive oil (VOO), n=181 or TMD. +. nuts, n=193) received nutritiona…

MaleApolipoprotein BMediterranean dietCoronary DiseaseDiet MediterraneanDieta mediterràniaApolipoprotein B/A-I ratiolaw.inventionCohort StudiesRandomized controlled triallawVirgin olive oilMedicineNutsCardiometabolic riskAged 80 and overBioquímica y tecnologíabiologyAnthropometryMiddle AgedLipidsBiochemistry and technology0021-9150virgin olive oilApolipoproteïnesFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineApolipoprotein BCohort studyRiskmedicine.medical_specialtyApolipoprotein B/A-IBioquímica i biotecnologiaInternal medicineMediterranean dietHumansPlant OilsOlive OilAgedApolipoproteins BApolipoprotein A-Ibusiness.industrynutritional and metabolic diseasesApolipoproteins bCardiometabolic riskClinical trialEndocrinologybiology.proteinbusinessOlive oil
researchProduct

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients Wi…

2018

Objective— Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48). Approach and Results— We performed an in vivo kinetic study with stable isotopes (D 8 -valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d). We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides an…

MaleApolipoprotein B-48Agonistmedicine.medical_specialtymedicine.drug_classhyperlipidemiasGene Expression030209 endocrinology & metabolism030204 cardiovascular system & hematologypatients03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusChylomicronsHyperlipidemiaAnimalsHumansMedicineDiacylglycerol O-AcyltransferaseProspective StudiesTriglycerides[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMice Inbred BALB Cliraglutidebusiness.industryLiraglutideCatabolismType 2 Diabetes Mellitus[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismPostprandial Periodmedicine.diseaseLipoprotein LipaseJejunumEndocrinologyPostprandialAdipose TissueDiabetes Mellitus Type 2kineticsdiabetes mellitusFemaleApolipoprotein B-48Carrier ProteinsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct